- Home
- MDCX vs IGC Comparison
MDCX vs IGC Comparison
Compare MDCX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- IGC
- Stock Information
- Founded
- MDCX 2008
- IGC 2005
- Country
- MDCX Canada
- IGC United States
- Employees
- MDCX N/A
- IGC N/A
- Industry
- MDCX
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- IGC Health Care
- Exchange
- MDCX Nasdaq
- IGC Nasdaq
- Market Cap
- MDCX 29.7M
- IGC 29.4M
- IPO Year
- MDCX N/A
- IGC N/A
- Fundamental
- Price
- MDCX $2.99
- IGC $0.34
- Analyst Decision
- MDCX Strong Buy
- IGC Strong Buy
- Analyst Count
- MDCX 1
- IGC 2
- Target Price
- MDCX $10.00
- IGC $3.75
- AVG Volume (30 Days)
- MDCX 14.9K
- IGC 387.6K
- Earning Date
- MDCX 01-01-0001
- IGC 02-12-2025
- Dividend Yield
- MDCX N/A
- IGC N/A
- EPS Growth
- MDCX N/A
- IGC N/A
- EPS
- MDCX N/A
- IGC N/A
- Revenue
- MDCX N/A
- IGC $1,183,000.00
- Revenue This Year
- MDCX N/A
- IGC N/A
- Revenue Next Year
- MDCX N/A
- IGC $13.38
- P/E Ratio
- MDCX N/A
- IGC N/A
- Revenue Growth
- MDCX N/A
- IGC N/A
- 52 Week Low
- MDCX $1.80
- IGC $0.27
- 52 Week High
- MDCX $3.23
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- IGC 44.69
- Support Level
- MDCX N/A
- IGC $0.31
- Resistance Level
- MDCX N/A
- IGC $0.36
- Average True Range (ATR)
- MDCX 0.00
- IGC 0.02
- MACD
- MDCX 0.00
- IGC -0.00
- Stochastic Oscillator
- MDCX 0.00
- IGC 42.71
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.